Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2

Figure 4

(a) Comparison of first day’s fold changes of blood samples of groups, considering nontreated group equal to 1 (other group is shown proportional to the nontreated group). (b) Comparison of last day’s fold changes of blood samples of groups, considering nontreated group equal to 1 (other group is shown proportional to nontreated group, ). (c) Comparison of last day’s fold changes of cardiac tissue samples of groups, considering nontreated group equal to 1 (other group is shown proportional to nontreated group, ). (d) Comparison of first day’s fold changes of blood samples of groups, considering healthy group equal to 1 (other group is shown proportional to the healthy group). (e) Comparison of last day’s fold changes of blood samples of groups, considering healthy group equal to 1 (other group is shown proportional to the healthy group, ). (f) Comparison of last day’s fold changes of cardiac tissue samples of groups, considering the healthy group equal to 1 (other group is shown proportional to the healthy group, ). (g) Comparison of first day’s fold changes of blood samples of groups, considering the CS group equal to 1 (other group is shown proportional to CS). (h) Comparison of last day’s fold changes of blood samples of groups, considering the CS group equal to 1 (other group is shown proportional to CS, , ¥ D50 vs. D200 ). (i) Comparison of last day’s fold changes of cardiac tissue samples of groups, considering the CS group equal to 1 (other group is shown proportional to CS, , ¥ D50 vs. D200, ).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)